1.
Clin Infect Dis
; 64(5): 680-683, 2017 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28011605
RESUMO
Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).